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Abstract
Only two families have been reported with biallelic TMEM260 variants segregating
with structural heart defects and renal anomalies syndrome (SHDRA). With a combi-
nation of genome, exome sequencing and RNA studies, we identified eight individuals
from five families with biallelic TMEM260 variants. Variants included one multi-exon
deletion, four nonsense/frameshifts, two splicing changes and one missense change.
Together with the published cases, analysis of clinical data revealed ventricular septal
defects (12/12), mostly secondary to truncus arteriosus (10/12), elevated creatinine
levels (6/12), horse-shoe kidneys (1/12) and renal cysts (1/12) in patients. Three
pregnancies were terminated on detection of severe congenital anomalies. Six
patients died between the ages of 6 weeks and 5 years. Using a range of stringencies,
carrier frequency for SHDRA was estimated at 0.0007–0.007 across ancestries. In
conclusion, this study confirms the genetic basis of SHDRA, expands its known muta-
tional spectrum and clarifies its clinical features. We demonstrate that SHDRA is a
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severe condition associated with substantial mortality in early childhood and
characterised by congenital cardiac malformations with a variable renal phenotype.
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1 | INTRODUCTION
TMEM260 is a 79.5 kDa protein with eight transmembrane spans
(www.uniprot.org/uniprot/Q9NX78) located mainly in the nucleo-
plasm and within focal adhesion sites (www.proteinatlas.org).1
TMEM260 encodes at least four protein-coding transcripts. Of these,
two (ENST00000261556.11 and ENST00000538838.5) are consid-
ered to be the main transcripts. They differ in the utilisation of an
internal exon as well as the final three exons, which in the short iso-
form are non-coding.
Five individuals from two families with biallelic truncating TMEM260
variants and brain, cardiac, renal, and digit abnormalities were reported in
2017.2 The condition is now listed on OMIM as “structural heart defects
and renal anomalies syndrome” (SHDRA; MIM #617478). Notably, the
variants in both families mapped to the long isoform, raising the possibil-
ity of SHDRA being an isoform-specific disorder. Since the original
publication, there have been no further reports in the literature. Knowl-
edge about the variant and the clinical spectrum of this condition is
therefore limited (Supplementary background). In this study, we describe
eight affected individuals from five families, confirming that biallelic
TMEM260 loss of function variants cause SHDRA and helping to define
its clinical spectrum.
2 | MATERIALS AND METHODS
Whole genome sequencing in Families 1 and 2 was performed as part
of the 100 000 genomes project (100KGP; https://doi.org/10.6084/
m9.figshare.4530893.v6, Cambridge South REC: 14/EE/1112). Fami-
lies 3–5 were identified via whole exome sequencing (WES) pipelines
and international collaboration. RNA analysis was performed for Fam-
ily 1 using PaxGene blood samples. Carrier frequency for SHDRA was
calculated as described previously.3 More details are in Supplemental
methods and Tables S1-S2.
3 | RESULTS
3.1 | Compound-heterozygous TMEM260 variants
in foetuses with congenital heart anomalies
In F1-II-3 (Figure 1A), type I truncus arteriosus (TA) with pulmonary
stenosis and ventricular septal defect (VSD) were detected on antena-
tal anomaly scan at 20 weeks gestation (Table 1). The pregnancy was
terminated at 21 weeks. Post-mortem examination confirmed the car-
diac anomalies (Figure S1) and did not reveal any other abnormalities.
In F1-II-4 a large peri-membranous outlet VSD, type I TA with small
pulmonary trunk and small pulmonary artery branches were detected
antenatally and the pregnancy was terminated at 24 weeks gestation.
Post-mortem examination confirmed the cardiac anomalies and rev-
ealed a horseshoe kidney. The placenta was also abnormal with a
two-vessel cord and omphalomesenteric duct remnant.
Trio WGS was performed as part of the 100KGP on F1-II-4 and
both parents. Although the initial analysis focussing on several panels
from PanelApp was negative, a scan for Mendelian inconsistencies
highlighted an apparently homozygous NM_017799.4:c.344G > A:p.
(Arg115Lys) TMEM260 variant in F1-II-4 (Figure 1B). As expected, the
father (F1-I-1) was heterozygous for the c.344G > A TMEM260 vari-
ant, but the mother (F1-I-2) was apparently homozygous for the wild-
type allele. Review of read alignments revealed a maternally inherited
4891 bp deletion (Figure 1B) encompassing exons 2–3. Sanger
sequencing and digital droplet PCR confirmed that F1-II-3 was also
hemizygous for c.344G > A. Neither of the unaffected brothers
(F1-II-1 and F1-II-2) had inherited both TMEM260 variants.
Although the c.344G > A variant was initially annotated as p.
Arg115Lys, it involves the last base of exon 3 and results in a drop in
the predicted splicing efficiency (MaxEntScan: 9.65 ! 2.69). We,
therefore, performed RT-PCR on peripheral blood sample from F1-I-1,
which showed the presence of two bands, with only the larger band
seen in controls (Figure 1C). Sanger sequencing confirmed exon 3 skip-
ping (Figure 1D, Figure S2), resulting in a frameshift of exon 4 (p.
Val65AlafsTer32). Similarly, the expected exon 1–4 junction was
detected by RT-PCR in the maternal sample (Figure S3), resulting in p.
(Glu55PhefsTer20). Collectively, the genetic studies, RNA analysis and
similarity of the foetuses' phenotypes with features reported
previously,2 strongly suggest these TMEM260 variants are disease-
causing.
3.2 | Identification of additional SHDRA patients
To expand the cohort of patients with SHDRA we interrogated the
100KGP database further and identified a homozygous c.1410C > G:
p.Tyr470Ter TMEM260 variant in Family 2 (Figure 1E). F2-II-2
exhibited a common arterial trunk, tricuspid atresia, VSD, partial
anomalous pulmonary venous connection, bilateral hearing loss, global
developmental delay, protein losing enteropathy and deteriorating
renal function from the age of 15 months (Figure S4). Multi-organ


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 PAGNAMENTA ET AL.
failure following cardiac surgery led to death at age 5 (Table S1, Sup-
plementary Case Histories).
Through international collaboration, we uncovered three further
families ascertained via WES (Figure 1E,F). This included a novel
c.1644del:p.Pro549LeufsTer46 allele in trans with the previously
described2 c.1393C > T:p.Gln465Ter in a sib-pair (Family 3). The elder
brother presented with type I TA, mild truncal valve insufficiency, a
large VSD, with normal renal function (max. Creatinine of 39 μmoL/L)
and normal neurodevelopment at the of 5 years. The younger brother
was born with Type I TA, mild to moderate truncal valve insufficiency
and a large VSD (Video S1). A few days after cardiac surgery he devel-
oped severe chylothorax and progressive renal failure (Figure S5) and
died at approaching 4 months from multi-organ failure. In Family 4 we
identified previously described2 homozygous c.1698_1701del:p.
Tyr567ThrfsTer27 TMEM260 variant in 2 year old boy with Type I TA
and VSD, and normal renal function (maximum creatinine level of
37 μmoL/L) and normal neurodevelopment. In Family 5 we identified
novel compound-heterozygous TMEM260 variants: c.193-2A > G and
c.1744G > C:p.Glu582Gln in a girl who died at the age of 4 months.
The missense variant is predicted damaging by SIFT/PolyPhen2. The
girl was born with TA type I, hypoplastic right ventricle, small main
and branch pulmonary arteries, VSD and atrial septal defect. During
her neonatal period, she developed necrotizing enterocolitis with per-
foration of transverse colon, renal impairment (Figure S6) and died at
4 months. Type I TA and VSD were detected antenatally in the pro-
band's sibling (Figure S7) and the pregnancy was terminated at
22 weeks. The same compound-heterozygous TMEM260 variants
were also identified in the foetus.
3.3 | SHDRA carrier frequency is 0.7–7 per 1000
individuals
Next, we estimated the carrier frequency of SHDRA using a range of
stringency thresholds (Figure S8A). The most stringent criteria
included only variants that would be predicted to result in loss-of-
F IGURE 1 Clinical and variant spectrum of SHDRA. (A) Pedigree of Family 1. (B) IGV screenshot showing Illumina read-alignments supporting
a rare deletion of TMEM260. Split read pairs (red) indicate the start and end of the deletion, concomitant with a drop in coverage. The deletion is
inherited from the mother and resolves the Mendelian inconsistency. Figure S9 shows a zoomed in view of c.344G > A. (C) RT-PCR results for
Family 1. A larger band is seen in all samples, representing the wild-type allele. Smaller bands are seen in both paternal and maternal samples.
(D) Custom UCSC session showing position of the maternal deletion and paternal c.344G > A. RT-PCR primer positions are indicated by in silico
PCR. FASTA sequences generated by Sanger sequencing (Blat Search) indicate exon 3 skipping in the father and exon 2–3 skipping in the mother.
(E) Pedigrees and genetic segregation results for four other families with biallelic TMEM260 variants. NA, DNA unavailable; *, sequencing as part
of the 100KGP; +, exome sequencing. (F) Distribution of variants found in this study. c.1393C > T and c.1689_1701delCTAT (double circles)
were previously described.2 The last three exons of isoform ENST00000538838 (grey) are non-coding, hence the only variants to affect both
isoforms are c.193-2A > G, c.344G > A and the deletion [Colour figure can be viewed at wileyonlinelibrary.com]
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function (without low-confidence flags) and known ClinVar patho-
genic or likely pathogenic variants. The least stringent criteria included
all variants with a CADD score over 30, a spliceAI score over 0.8 as
well as loss-of-function alleles and ClinVar pathogenic and likely path-
ogenic alleles. This analysis showed that per-ancestry gene carrier rate
(GCR) for TMEM260 ranges between 0.001 and 0.007 for least strin-
gent parameters to 0.0007–0.005 for the most stringent. Only 16/94
predicted deleterious variants using the lowest stringency threshold
are missense variants (Figure S8B). The GCR was found to be higher
in individuals with African/African–American ancestry and lowest in
Finnish ancestry. The higher GCR in the African/African–American
population is due to a possible founder variant (p.Lys696ThrfsTer7,
rs568247949) which has “Likely pathogenic” status in ClinVar with a
single submission (SCV000992576.2).
4 | DISCUSSION
We present eight individuals, from five independent families, with
biallelic TMEM260 variants (Figure 1). In combination with clinical data
published previously,2 our results suggest congenital cardiac mal-
formations to be the most consistent phenotype of SHDRA. All
12 patients are reported to have VSD and 10/12 had TA (Table 1). In
most of these patients, VSD is likely to be secondary to TA. Notably, TA
is one of the rarest congenital cardiac anomalies with few known genetic
associations in NKX2-5,4 NKX2-6,5 GATA66 as well as TBX1.7 Interest-
ingly, TMEM260, is predicted to be one of 1442 target genes for GATA6
predicted using known transcription factor binding site motifs from the
TRANSFAC dataset.8 The JASPAR database of transcription factor bind-
ing sites predicts a GATA6 binding site within intron 5 of TMEM260
although the functionality of this motif is unknown.9
Our results show that the renal phenotype of SHDRA is highly
variable. Horseshoe kidney and cysts were noted in one patient each.
The renal failure seen in three individuals could be pre-renal injury
and acute tubular necrosis secondary to cardiac failure and systemic
illness. However, the decline in glomerular filtration prior to the onset
of cardiac failure in F2-II-2 suggests the possibility of underlying renal
dysfunction. Further studies should address whether the variable
renal involvement is secondary to cardiac complications or a primary
component of the condition. The intra-familial variability in renal phe-
notype indicates that this may not be solely due to the precise
TMEM260 variant(s) that are involved. A more likely hypothesis is that
there is a congenital predisposition to renal failure, leaving the individ-
ual vulnerable to a rapid deterioration that can be precipitated by clin-
ical (e.g., cardiac/intestinal) insults.
The combination of congenital heart disease, especially con-
otruncal defects with renal abnormalities is unusual. Conotruncal
abnormalities are seen in 22q11.21 deletion syndrome, in which renal
abnormalities, such as hypoplasia or agenesis of the kidney,
multicystic dysplasia and vesicoureteral reflux, are thought to occur in
over 30% of patients.10 Another dominant disorder with some pheno-
typic overlap, including TA and hypoplastic kidneys, is Townes-Brocks
syndrome (MIM #107480) due to heterozygous mutations in
SALL1.11,12 The association of cardiac, cerebral and renal mal-
formations is also reminiscent of ciliopathies, although generally the
cardiac features linked to these group of disorders do not include TA.
Antenatal detection of severe congenital malformations led to
termination of pregnancy in three cases described here. Out of nine
live born pregnancies, six patients died within the age ranges of
6 weeks to 5 years. One of the two individuals whom survived to
5-years old (F2-II-2) had developmental delay and hearing loss. How-
ever, due to insufficient numbers it is difficult to confidently associate
these features with SHDRA. We note that two other individuals in
the present study who survived beyond their first year, were cogni-
tively normal. Although facial dysmorphism was reported in 1/4 of the
original cohort, that feature was not replicated here.
This study substantially expands the known mutation spectrum of
SHDRA. Including the patients presented here, a total of eight differ-
ent TMEM260 variants in 12 individuals from seven families have now
been identified (Figure 1F). Of these, two variants are stop-gains, two
are frameshifts, one is a multi-exon deletion, two disrupt splicing and
one is missense. All variants are supported by in silico tools, including
CADD scores, which are 28.3–41 (Table 1). The distribution of the
variants confirms that variants affecting only the longer isoform are
sufficient to cause SHDRA.
We show that the carrier frequency for SHDRA could be up to 1 in
140 in certain populations (Figure S8). This analysis also identified a
potential founder variant in the African/African–American population
that requires further functional studies to validate its “Likely Pathogenic”
status in ClinVar. The c.1698_1701del seen in Family 4 and in an Arabic
family described previously2 may also represent a founder mutation.
In conclusion, our description of five families with biallelic TMEM260
variants confirms the genetic basis of SHDRA and helps delineate the
mutational/phenotypic spectrum of the condition. The strong association
with TA has important implications for genetic counselling, prenatal diag-
nostics as well as postnatal targeted genetic testing.
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